Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk

Expert Review of Clinical Immunology

Volumn 10, Issue 2, 2014, Pages 307-315

  Ingegnoli, Francesca ^a   Gualtierotti, Roberta ^a   Artusi, Carolina ^a   Lubrano, Ennio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

ankylosing spondylitis; anti TNF ; cardiovascular disease; cardiovascular risk; DMARDs; methotrexate; NSAIDs; psoriatic arthritis; spondylarthritis; statin

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; PHYSICIAN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; SPONDYLARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; RISK; SPONDYLARTHRITIS;

EID: 84893094919     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.875468     Document Type: Review

References (91)

1. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41(6):1103-10
2. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review. Ann Rheum Dis 2013;72(2):211-16
3. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34(3):585-92
4. Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosclerosis 2010;212(1):305-9
5. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: Roles of inflammation and dyslipidemia. J Autoimmun 2007;28(2-3): 69-75
6. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69(2): 325-31
7. Maksymowych WP. Spondyloarthritis in 2012: Advances in pathogenesis through animal models and imaging. Nat Rev Rheumatol 2013;9(2):72-4
8. Qaiyumi S, Hassan ZU, Toone E. Seronegativespondyloarthropathies in lone aortic insufficiency. Arch Intern Med 1985; 145(5):822-4
9. Bergfeldt L, Insulander P, Lindblom D, et al. HLA-B27: An important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities. Am J Med 1988;85(1):12-18
10. Bergfeldt L. HLA B27-Associated rheumatic diseases with severe cardiac bradyarrhythmias. Clinical features and prevalence in 223 men with permanent pacemakers. Am J Med 1983;75(2): 210-15
11. Bergfeldt L, Moller E. Complete heart block-Another HLA B27 associated disease manifestation. Tissue Antigens 1983;21(5): 385-90
12. Brown MA. Non-major-histocompatibilitycomplex genetics of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20(3): 611-21
13. Rahman P, Siannis F, Butt C, et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006; 65(7):919-23
14. Butt C, Gladman D, Rahman P. PPA R-gamma gene polymorphisms and psoriatic arthritis. J Rheumatol 2006;33(8): 1631-3
15. Smith JA, Marker-Hermann E, Colbert RA. Pathogenesis of ankylosing spondylitis: Current concepts. Best Pract Res Clin Rheumatol 2006;20(3):571-91
16. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39(11):1329-37
17. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007;74(3):304-5
18. Wang X, Lin Z, Wei Q, et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009;29(11): 1343-7
19. Singh R, Aggarwal A, Misra R. Th1/ Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007; 34(11):2285-90
20. Melis L, Elewaut D. Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: Which cells drive disease? Arthritis Res Ther 2009;11(3):233
21. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008;58(8):2307-17
22. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: A literature review. J Rheumatol 1999;26(4): 966-70
23. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26(4):980-4
24. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007;13(3):242-4
25. Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010; 69(3):618-23
26. Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 1981;40(1):66-9
27. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112(21):3337-47
28. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352(16):1685-95
29. Pasceri V, Yeh ET. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation 1999;100(21):2124-6
30. Weyand CM, Goronzy JJ, Liuzzo G, et al. T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001;76(10): 1011-20
31. Kao AH, Sabatine JM, Manzi S. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 2003; 15(5):519-27
32. Winer S, Chan Y, Paltser G, et al. Normalization of obesity-Associated insulin resistance through immunotherapy. Nat Med 2009;15(8):921-9
33. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15(8):930-9
34. Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: Relationship with metabolic factors and complications. J Mol Med 2012;90(2):175-86
35. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11(2):98-107
36. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999;340(2):115-26
37. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30(2):260-8
38. Holm PW, Slart RH, Zeebregts CJ, et al. Atherosclerotic plaque development and instability: A dual role for VEGF. Ann Med 2009;41(4):257-64
39. Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(10):1623-9
40. Wanders A, Heijde D, Landewe R, et al. Nonsteroidalantiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005;52(6):1756-65
41. Lassus A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease. Curr Med Res Opin 1976;4(1):65-9
42. Leatham PA, Bird HA, Wright V, Fowler PD. The run-in period in trial design: A comparison of two non-steroidal anti-inflammatory agents in psoriatic arthropathy. Agents Actions 1982;12(1-2): 221-4
43. Hopkins R, Bird HA, Jones H, et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985;44(3): 189-93
44. Clark DW, Coulter DM. Psoriasis associated with rofecoxib. Arch Dermatol 2003;139(9):1223
45. Ben-Chetrit E, Rubinow A. Exacerbation of psoriasis by ibuprofen. Cutis 1986;38(1):45
46. Meyerhoff JO. Exacerbation of psoriasis with meclofenamate. N Engl J Med 1983; 309(8):496
47. Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: Evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19(1 Suppl 22):S17-20
48. Radner H, Ramiro S, Buchbinder R, et al. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. Cochrane Database Syst Rev 2012;1:CD008951
49. Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: A meta-Analysis. Arthritis Res Ther 2006;8(5):R153
50. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296(13):1633-44
51. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-Analysis of randomised trials. BMJ 2006;332(7553): 1302-8
52. Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3(4):395-405
53. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52(20):1628-36
54. Goodson NJ, Brookhart AM, Symmons DP, et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis 2009;68(3): 367-72
55. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013;2: CD004524
56. Micha R, Imamura F, Wyler vonBallmoos M, et al. Systematic review and meta-Analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108(9):1362-70
57. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33(7):1422-30
58. Lubrano E, Scarpa R. Psoriatic arthritis: Treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 2012;64(2):107-12
59. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39(12):2004-12
60. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42(11):2325-9
61. Kim JY, Cho HJ, Sir JJ, et al. Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia. Cardiovasc Res 2009;82(3):550-60
62. Tabit CE, Holbrook M, Shenouda SM, et al. Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease. Vasc Med 2012;17(2):101-7
63. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50(6):1939-50
64. Feng H, Li XY, Zheng JR, et al. Inhibition of the nuclear factor-kappaB signaling pathway by leflunomide or triptolide also inhibits the anthralin-induced inflammatory response but does not affect keratinocyte growth inhibition. Biol Pharm Bull 2005; 28(9):1597-602
65. Grisar J, Aringer M, Koller MD, et al. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004;63(12):1632-7
66. Spadaro A, Riccieri V, Sili-Scavalli A, et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study. Clin Exp Rheumatol 1995;13(5):589-93
67. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64(6):859-64
68. Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28(10):2274-82
69. Zanotti I, Greco D, Lusardi G, et al. Cyclosporine a impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion. PLoS ONE 2013;8(8):e71572
70. Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37(1):161-6
71. Mazzoccoli G, Notarsanto I, de Pinto GD, et al. Anti-Tumor necrosis factor-Alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 2010; 5(6):495-500
72. van Eijk IC, Peters MJ, Serné EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009;68(3):362-6
73. Capkin E, Karkucak M, Kose MM, et al. Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis. Rheumatol Int 2012;32(2):431-4
74. Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008;47(8):1203-7
75. Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-Alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: A controlled study. Hypertension 2010;55(2):333-8
76. Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology 2013;52(1):204-9
77. Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-Alpha therapy may not improve arterial stiffness in patients with AS: A 24-week follow-up. Rheumatology 2012; 51(5):910-14
78. Pieringer H, Stuby U, Pohanka E, Biesenbach G. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin Rheumatol 2010;29(7): 723-7
79. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33(12):2440-6
80. Kiortsis DN, Mavridis AK, Filippatos TD, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33(5):921-3
81. Mathieu S, Dubost JJ, Tournadre A, et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010;77(1): 50-2
82. van Eijk IC, de Vries MK, Levels JH, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009;60(5): 1324-30
83. Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-Alpha blockade. Clin Rheumatol 2010;29(7):763-70
84. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010;37(7):1386-94
85. Lubrano E, Soriano E, FitzGerald O. Can traditional DMARDs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol 2013;31(Suppl 78):S54-8
86. Spadaro A, Lubrano E. Beyond anti-TNF-Alpha agents in psoriatic arthritis. Expert Rev Clin Immunol 2013;9(6):507-9
87. Castro KR, Aikawa NE, Saad CG, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol 2011;2011:352686
88. Angel K, Provan SA, Hammer HB, et al. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 2011;25(4):511-17
89. Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res 2013; 56(2-3):348-57
90. van Denderen JC, Peters MJ, van Halm VP, et al. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 2006;65(5):695-6
91. Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012;64(9):36-46